The implantable infusion pumps market size has grown strongly in recent years. It will grow from $20.32 billion in 2025 to $21.73 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increasing prevalence of chronic pain conditions, rising incidence of diabetes, growth in oncology treatment procedures, advancements in implantable pump technology, expansion of specialty clinical care.
The implantable infusion pumps market size is expected to see strong growth in the next few years. It will grow to $28.25 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing adoption of smart infusion technologies, rising demand for remote patient monitoring, expansion of personalized dosing regimens, growing investments in digital therapeutics, increasing use of implantable pumps in homecare settings. Major trends in the forecast period include increasing adoption of programmable infusion pumps, rising demand for long-term pain management solutions, growing use of smart and connected pumps, expansion of implantable insulin delivery systems, enhanced focus on dose accuracy.
The growing aging population is expected to drive the growth of the implantable infusion pumps market in the coming years. The aging population refers to the percentage of individuals aged 65 and older compared to those between 18 and 64 who are employed. The rise in the aging population is primarily due to increased life expectancy, thanks to advances in healthcare and living standards, leading to more people living longer. Implantable infusion pumps are commonly used to manage chronic conditions, which means a larger aging population translates to a greater pool of potential patients who could benefit from these devices. For example, in February 2025, Eurostat, the Luxembourg-based statistical office of the European Union, reported that the EU had an estimated population of around 449 million people in 2024, with over one-fifth (21.6%) of the population aged 65 or older. The median age of the EU population was 44.7 years, and the old-age dependency ratio in the EU increased by 0.5 percentage points between 2023 and 2024, rising from 33.4% to 33.9%. As a result, the increase in the aging population is contributing to the growth of the implantable infusion pumps market.
Leading companies in the implantable infusion pump market are focusing on the development of new products, such as insulin pumps, to address a broader customer base, boost sales, and increase revenue. Insulin pumps are medical devices designed to assist individuals with diabetes in managing their blood sugar levels. Notably, in April 2023, Medtronic, an Ireland-based medical device company, announced the FDA approval for the MiniMed 780G System featuring meal detection technology. This product distinguishes itself by setting the lowest glucose target (as low as 100 mg/dL) among all automated insulin pumps available in the market, aiming to closely mirror the average glucose levels of individuals without diabetes. The system operates on a treat-to-target basis, automatically making basal insulin adjustments and autocorrections to attain a specific target. Additionally, it stands out as the only pump featuring an infusion set that can be worn comfortably for an extended period of up to 7 days. This extended wear time is facilitated by advanced materials that minimize insulin preservative loss, maintaining consistent insulin flow and stability while reducing the likelihood of infusion set occlusion.
In May 2025, Boston Scientific, a US-based medical device company, acquired Intera Oncology, Inc. for approximately $172 million. Through this acquisition, Boston Scientific gains Intera Oncology’s specialized Intera 3000 Hepatic Artery Infusion Pump and its associated floxuridine drug. This integration enhances Boston Scientific’s interventional oncology portfolio by adding a proven, targeted Hepatic Artery Infusion (HAI) therapy system for treating liver tumors. Intera Oncology, Inc., a US-based company, specializes in implantable infusion pumps and chemotherapy drug delivery systems and has a strong track record in hepatic artery infusion therapy.
Major companies operating in the implantable infusion pumps market are Medtronic plc, Boston Scientific Corporation, Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Smiths Medical a Smiths Group company, Terumo Corporation, Johnson & Johnson, Greatbatch Medical, Primetech Corporation, Flowonix Medical Inc., F. Hoffmann-La Roche Ltd, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Micrel Medical, Insulet Corporation, ICU Medical Inc., Becton Dickinson and Company (BD), Roche Diagnostics International AG, Abbott Laboratories, Hospira, Teleflex Incorporated, C. R. Bard Inc., AngioDynamics Inc., Merit Medical Systems Inc., NIPRO Medical Corporation, IRadimed Corporation, Zyno Medical, Tricumed Medizintechnik GmbH, Q Core Medical Ltd., Ivenix Inc., Tandem Diabetes Care Inc.
North America was the largest region in the implantable infusion pumps market in 2025. Asia-Pacific was the second-largest region in the implantable infusion pumps market. The regions covered in the implantable infusion pumps market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable infusion pumps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the implantable infusion pumps market by increasing costs of imported electronic modules, sensors, battery components, and precision pump mechanisms. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported high-value medical components, while Asia-Pacific faces cost pressures on device exports. These tariffs are increasing device acquisition costs and slowing replacement cycles. However, they are also supporting domestic assembly, regional component sourcing, and innovation in cost-optimized implantable pump systems.
The implantable infusion pumps market research report is one of a series of new reports that provides implantable infusion pumps market statistics, including implantable infusion pumps industry global market size, regional shares, competitors with a implantable infusion pumps market share, detailed implantable infusion pumps market segments, market trends and opportunities, and any further data you may need to thrive in the implantable infusion pumps industry. This implantable infusion pumps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Implantable infusion pumps are advanced drug delivery systems designed to be surgically implanted within a patient's body. These devices are responsible for controlled and precise administration of medication directly into the bloodstream.
The implantable infusion pumps market is categorized into several types, including patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and other variations. For instance, insulin pumps are small devices implanted under the skin during surgical procedures to continuously deliver insulin for patients with diabetes. These implantable infusion pumps find applications across various medical fields, including oncology, pediatrics/neonatology, gastroenterology, hematology, diabetes, and more. They are commonly used in healthcare settings such as hospitals, ambulatory surgical centers, and specialty clinics to provide effective and precise drug delivery to patients.
The implantable infusion pumps market consists of sales of instruments such as patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The implantable infusion pumps market size is expected to see strong growth in the next few years. It will grow to $28.25 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing adoption of smart infusion technologies, rising demand for remote patient monitoring, expansion of personalized dosing regimens, growing investments in digital therapeutics, increasing use of implantable pumps in homecare settings. Major trends in the forecast period include increasing adoption of programmable infusion pumps, rising demand for long-term pain management solutions, growing use of smart and connected pumps, expansion of implantable insulin delivery systems, enhanced focus on dose accuracy.
The growing aging population is expected to drive the growth of the implantable infusion pumps market in the coming years. The aging population refers to the percentage of individuals aged 65 and older compared to those between 18 and 64 who are employed. The rise in the aging population is primarily due to increased life expectancy, thanks to advances in healthcare and living standards, leading to more people living longer. Implantable infusion pumps are commonly used to manage chronic conditions, which means a larger aging population translates to a greater pool of potential patients who could benefit from these devices. For example, in February 2025, Eurostat, the Luxembourg-based statistical office of the European Union, reported that the EU had an estimated population of around 449 million people in 2024, with over one-fifth (21.6%) of the population aged 65 or older. The median age of the EU population was 44.7 years, and the old-age dependency ratio in the EU increased by 0.5 percentage points between 2023 and 2024, rising from 33.4% to 33.9%. As a result, the increase in the aging population is contributing to the growth of the implantable infusion pumps market.
Leading companies in the implantable infusion pump market are focusing on the development of new products, such as insulin pumps, to address a broader customer base, boost sales, and increase revenue. Insulin pumps are medical devices designed to assist individuals with diabetes in managing their blood sugar levels. Notably, in April 2023, Medtronic, an Ireland-based medical device company, announced the FDA approval for the MiniMed 780G System featuring meal detection technology. This product distinguishes itself by setting the lowest glucose target (as low as 100 mg/dL) among all automated insulin pumps available in the market, aiming to closely mirror the average glucose levels of individuals without diabetes. The system operates on a treat-to-target basis, automatically making basal insulin adjustments and autocorrections to attain a specific target. Additionally, it stands out as the only pump featuring an infusion set that can be worn comfortably for an extended period of up to 7 days. This extended wear time is facilitated by advanced materials that minimize insulin preservative loss, maintaining consistent insulin flow and stability while reducing the likelihood of infusion set occlusion.
In May 2025, Boston Scientific, a US-based medical device company, acquired Intera Oncology, Inc. for approximately $172 million. Through this acquisition, Boston Scientific gains Intera Oncology’s specialized Intera 3000 Hepatic Artery Infusion Pump and its associated floxuridine drug. This integration enhances Boston Scientific’s interventional oncology portfolio by adding a proven, targeted Hepatic Artery Infusion (HAI) therapy system for treating liver tumors. Intera Oncology, Inc., a US-based company, specializes in implantable infusion pumps and chemotherapy drug delivery systems and has a strong track record in hepatic artery infusion therapy.
Major companies operating in the implantable infusion pumps market are Medtronic plc, Boston Scientific Corporation, Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Smiths Medical a Smiths Group company, Terumo Corporation, Johnson & Johnson, Greatbatch Medical, Primetech Corporation, Flowonix Medical Inc., F. Hoffmann-La Roche Ltd, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Micrel Medical, Insulet Corporation, ICU Medical Inc., Becton Dickinson and Company (BD), Roche Diagnostics International AG, Abbott Laboratories, Hospira, Teleflex Incorporated, C. R. Bard Inc., AngioDynamics Inc., Merit Medical Systems Inc., NIPRO Medical Corporation, IRadimed Corporation, Zyno Medical, Tricumed Medizintechnik GmbH, Q Core Medical Ltd., Ivenix Inc., Tandem Diabetes Care Inc.
North America was the largest region in the implantable infusion pumps market in 2025. Asia-Pacific was the second-largest region in the implantable infusion pumps market. The regions covered in the implantable infusion pumps market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable infusion pumps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the implantable infusion pumps market by increasing costs of imported electronic modules, sensors, battery components, and precision pump mechanisms. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported high-value medical components, while Asia-Pacific faces cost pressures on device exports. These tariffs are increasing device acquisition costs and slowing replacement cycles. However, they are also supporting domestic assembly, regional component sourcing, and innovation in cost-optimized implantable pump systems.
The implantable infusion pumps market research report is one of a series of new reports that provides implantable infusion pumps market statistics, including implantable infusion pumps industry global market size, regional shares, competitors with a implantable infusion pumps market share, detailed implantable infusion pumps market segments, market trends and opportunities, and any further data you may need to thrive in the implantable infusion pumps industry. This implantable infusion pumps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Implantable infusion pumps are advanced drug delivery systems designed to be surgically implanted within a patient's body. These devices are responsible for controlled and precise administration of medication directly into the bloodstream.
The implantable infusion pumps market is categorized into several types, including patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and other variations. For instance, insulin pumps are small devices implanted under the skin during surgical procedures to continuously deliver insulin for patients with diabetes. These implantable infusion pumps find applications across various medical fields, including oncology, pediatrics/neonatology, gastroenterology, hematology, diabetes, and more. They are commonly used in healthcare settings such as hospitals, ambulatory surgical centers, and specialty clinics to provide effective and precise drug delivery to patients.
The implantable infusion pumps market consists of sales of instruments such as patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Implantable Infusion Pumps Market Characteristics
3. Implantable Infusion Pumps Market Supply Chain Analysis
4. Global Implantable Infusion Pumps Market Trends and Strategies
5. Implantable Infusion Pumps Market Analysis of End Use Industries
7. Global Implantable Infusion Pumps Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Implantable Infusion Pumps Total Addressable Market (TAM) Analysis for the Market
9. Implantable Infusion Pumps Market Segmentation
10. Implantable Infusion Pumps Market Regional and Country Analysis
11. Asia-Pacific Implantable Infusion Pumps Market
12. China Implantable Infusion Pumps Market
13. India Implantable Infusion Pumps Market
14. Japan Implantable Infusion Pumps Market
15. Australia Implantable Infusion Pumps Market
16. Indonesia Implantable Infusion Pumps Market
17. South Korea Implantable Infusion Pumps Market
18. Taiwan Implantable Infusion Pumps Market
19. South East Asia Implantable Infusion Pumps Market
20. Western Europe Implantable Infusion Pumps Market
21. UK Implantable Infusion Pumps Market
22. Germany Implantable Infusion Pumps Market
23. France Implantable Infusion Pumps Market
24. Italy Implantable Infusion Pumps Market
25. Spain Implantable Infusion Pumps Market
26. Eastern Europe Implantable Infusion Pumps Market
27. Russia Implantable Infusion Pumps Market
28. North America Implantable Infusion Pumps Market
29. USA Implantable Infusion Pumps Market
30. Canada Implantable Infusion Pumps Market
31. South America Implantable Infusion Pumps Market
32. Brazil Implantable Infusion Pumps Market
33. Middle East Implantable Infusion Pumps Market
34. Africa Implantable Infusion Pumps Market
36. Implantable Infusion Pumps Market Competitive Landscape and Company Profiles
37. Implantable Infusion Pumps Market Other Major and Innovative Companies
40. Implantable Infusion Pumps Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Implantable Infusion Pumps Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses implantable infusion pumps market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for implantable infusion pumps? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The implantable infusion pumps market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Patient-Controlled Analgesia (PCA) Pumps; Enteral Pumps; Insulin Pumps; Elastomeric Pumps; Syringe Pumps; Other Types2) By Applications: Oncology; Pediatrics Or Neonatology; Gastroenterology; Hematology; Diabetes; Other Applications
3) By End User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics
Subsegments:
1) By Patient-Controlled Analgesia (PCA) Pumps: Morphine PCA Pumps; Fentanyl PCA Pumps; Other Opioid PCA Pumps2) By Enteral Pumps: Tube Feeding Pumps; Syringe-based Enteral Pumps; Continuous Or Intermittent Feeding Pumps
3) By Insulin Pumps: Insulin Delivery Pumps; Insulin Patch Pumps; Smart Insulin Pumps
4) By Elastomeric Pumps: Disposable Elastomeric Pumps; Reusable Elastomeric Pumps
5) By Syringe Pumps: Small Volume Syringe Pumps; Large Volume Syringe Pumps
6) By Other Types: Chemotherapy Infusion Pumps; Antibiotic Infusion Pumps; Pain Management Pumps
Companies Mentioned: Medtronic plc; Boston Scientific Corporation; Baxter International Inc.; B. Braun Melsungen AG; Fresenius Kabi AG; Smiths Medical a Smiths Group company; Terumo Corporation; Johnson & Johnson; Greatbatch Medical; Primetech Corporation; Flowonix Medical Inc.; F. Hoffmann-La Roche Ltd; Shenzhen Mindray Bio-Medical Electronics Co. Ltd.; Micrel Medical; Insulet Corporation; ICU Medical Inc.; Becton Dickinson and Company (BD); Roche Diagnostics International AG; Abbott Laboratories; Hospira; Teleflex Incorporated; C. R. Bard Inc.; AngioDynamics Inc.; Merit Medical Systems Inc.; NIPRO Medical Corporation; IRadimed Corporation; Zyno Medical; Tricumed Medizintechnik GmbH; Q Core Medical Ltd.; Ivenix Inc.; Tandem Diabetes Care Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Implantable Infusion Pumps market report include:- Medtronic plc
- Boston Scientific Corporation
- Baxter International Inc.
- B. Braun Melsungen AG
- Fresenius Kabi AG
- Smiths Medical a Smiths Group company
- Terumo Corporation
- Johnson & Johnson
- Greatbatch Medical
- Primetech Corporation
- Flowonix Medical Inc.
- F. Hoffmann-La Roche Ltd
- Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
- Micrel Medical
- Insulet Corporation
- ICU Medical Inc.
- Becton Dickinson and Company (BD)
- Roche Diagnostics International AG
- Abbott Laboratories
- Hospira
- Teleflex Incorporated
- C. R. Bard Inc.
- AngioDynamics Inc.
- Merit Medical Systems Inc.
- NIPRO Medical Corporation
- IRadimed Corporation
- Zyno Medical
- Tricumed Medizintechnik GmbH
- Q Core Medical Ltd.
- Ivenix Inc.
- Tandem Diabetes Care Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 21.73 Billion |
| Forecasted Market Value ( USD | $ 28.25 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
